**RUSH UNIVERSITY MEDICAL CENTER**

**ILLINOIS**

**REGISTRY OF**

**ANATOMIC PATHOLOGY**

 **CASE HISTORIES AND DIAGNOSES**

**MARCH 30, 2015**

**Case #1**

**PRESENTER:** Jorge Novo, MD

**ATTENDING:** Leonidas Arvanitis, MD

**CASE HISTORY:** A 55-year-old woman with a history of morning headaches, nausea and lethargy presents to the emergency department after a new onset-seizure. CT scan shows multiple cystic lesions with scattered calcifications in the cerebral hemispheres, basal ganglia, pons, and cerebellum. MRI shows multiple cysts with contrast enhancement, and white matter edema. After a stereotactic biopsy is performed, the patient undergoes resection of the lesion.

**DIAGNOSIS:** Leukoencephalopathy, Cerebral calcifications and Cysts (LCC).

**DISCUSSION:**

* LCC is a very rare leukoencephalopathy, with only 19 adult cases reported in the English literature, and only 13 with histopathologic examination. (range = 18-69, mean age = 34).
* Clinical presentation may present with acute neurologic symptoms simulating a stroke, or present with symptoms of mass effect mimicking a neoplasm.
* Initially characterized in 1996 by Labrune et. al. with the radiologic triad of:
	+ Progressive cerebral and cerebellar calcifications.
	+ Diffuse abnormal white matter signaling.
	+ Space-occupying cysts with mass effect.
* Kleinschmidt-DeMasters et. al. performed the most detailed histopathologic characterization of LCC in 2009. H&E examination shows:
	+ Gliosis.
	+ Rosenthal fibers.
	+ Angiomatous changes with fibrin thrombi and surrounding microinfarction.
	+ Calcifications.
* Current pathogenesis is unknown, although it is thought to be related to other small vessel disorders (CADASIL, CARASIL, HERNS, cerebral amyloid angiopathy). No genetic alterations have been currently identified.
* Prognosis is variable due to cyst expansion.
* Approximately 40% of patients undergo surgery for symptom management.
	+ If resectable, excision of the cysts is recommended.
	+ Shunting procedures (LP,VP, CVP, Ommaya) have been demonstrated to manage symptoms in patients with LCC.
* Differential diagnosis includes:
	+ Neoplastic prcesses (glioma, glioneuronal).
	+ Infectious (Toxoplasmosis, chronic neurocysticersosis).
	+ Vascular (thromboembolic, cerebral amyloid angiopathy, CADASIL).
	+ Metabolic (Fahr disease).
	+ Leukoencephalopathy (Coat’s plus syndrome)
		- Infancy or early childhood onset. Rare adult cases.
		- Similar radiologic triad + retinal telangiectasis or exudates.
		- Physical abnormalities, including skin and hair changes, lytic and sclerotic metaphyseal lesions, and vascular ectasias in stomach, small intestine and liver.
		- Characterized by CTC1 mutations.

**REFERENCES:**

1. Carare RO, Hawkes C a., Jeffrey M, Kalaria RN, Weller RO. Review: Cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol Appl Neurobiol. 2013;39:593-611.
2. Chen C, Kasper E, Berry-Candelario J, Eskandar E. Neurosurgical management of leukoencephalopathy, cerebral calcifications, and cysts: A case report and review of literature. Surg Neurol Int. 2011;2(Lcc).
3. Coeytaux A, Lobrinus J A, Horvath J, Kurian M, Vargas MI. Late onset of leucoencephalopathy with cerebral calcifications and cysts. J Neuroradiol. 2011;38(5):319-320.
4. Daglioglu E, Ergungor F, Hatipoglu HG, et al. Cerebral leukoencephalopathy with calcifications and cysts operated for signs of increased intracranial pressure: case report. Surg Neurol. 2009;72(2):177-181.
5. Jen J, Cohen a H, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology. 1997;49:1322-1330.
6. Kleinschmidt-Demasters BK, Cummings TJ, Hulette CM, Morgenlander JC, Corboy JR. Adult cases of leukoencephalopathy, cerebral calcifications, and cysts: expanding the spectrum of the disorder. J Neuropathol Exp Neurol. 2009;68(4):432-439.
7. Labrune P, Lacroix C, Goutières F, et al. Extensive brain calcifications, leukodystrophy, and formation of parenchymal cysts: a new progressive disorder due to diffuse cerebral microangiopathy. Neurology. 1996;46:1297-1301.
8. Livingston JH, Mayer J, Jenkinson E, et al. Leukoencephalopathy with calcifications and cysts: A purely neurological disorder distinct from coats plus. Neuropediatrics. 2014;45:175-182.
9. Miao Q, Paloneva T, Tuisku S, et al. Arterioles of the lenticular nucleus in CADASIL. Stroke. 2006;37(9):2242-7.
10. Nagae-Poetscher LM, Bibat G, Philippart M, et al. Leukoencephalopathy, cerebral calcifications, and cysts: new observations. Neurology. 2004;62:1206-1209.
11. Ooba H, Abe T, Hisamitsu Y, Fujiki M. Repeated cyst formation in a patient with leukoencephalopathy, cerebral calcifications, and cysts: effectiveness of stereotactic aspiration with Ommaya reservoir placement. J Neurosurg Pediatr. 2013;12(August):155-159.
12. Polvi A, Linnankivi T, Kivelä T, et al. Mutations in CTC1, encoding the CTS telomere maintenance complex component 1, cause cerebroretinal microangiopathy with calcifications and cysts. Am J Hum Genet. 2012;90:540-549.
13. Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2014;129:133-146.
14. Ummer K, Salam K a, Noone ML, Pradeep Kumar VG, Mampilly N, Sivakumar S. Leukoencephalopathy with intracranial calcifications and cysts in an adult: Case report and review of literature. Ann Indian Acad Neurol. 2010;13(4):299-301.
15. Wargon I, Lacour M-C, Adams D, Denier C. A small deep infarct revealing leukoencephalopathy, calcifications and cysts in an adult patient. J Neurol Neurosurg Psychiatry. 2008;79(2):224-225.

**Case # 2**

**PRESENTER:** Smita Patel, MD, PGY-2

**ATTENDING:** David Cimbaluk, MD

**DIAGNOSIS:** Collagenofibrotic Glomerulopathy (aka; collagen type-III glomerulopathy)

**IMPORTANT DIFFERENTIAL DIAGNOSIS BASED ON LIGHT MICROSCOPY, SPECIAL STAINS AND IMMUNOFLUORESCENCE:**

* Membranoproliferative Glomerulonephritis type I
* Diabetic Glomerulosclerosis
* Light chain deposition disease
* Amyloidosis
* Immunotactoid glomerulopathy

**IMPORTANT DIFFERENTIAL DIAGNOSIS BASED ULTRASTRUCTURAL FEATURES:**

* Fibronectin Glomerulopathy:
	+ Inherited disease with non-organized deposits of fibronectin in fine granular pattern in mesangium
* Nail-patella syndrome:
	+ Inherited disease with characteristic physical abnormalities
	+ The atypical collagen type-III accumulates in lamina densa of glomerular basement membrane (GBM) causing an irregular thickening of GBM

**KEY MORPHOLOGICAL FEATURES:**

**1) LIGHT MICROSCOPY:**

* Global expansion of the glomerular tufts by eosinophilic amorphous material
* Marked thickening of capillary walls causing narrowing of capillary lumens
* Mesangial expansion with or without mild cellularity

**2) SPECIAL STAINS:**

**PAS:** Weakly positive

**Jones:** Thickened capillary walls without splits, spikes or holes

**Immunofluorescence:** Negative or shows focal non-specific deposits of immunoglobulins (most commonly IgM) and complement components

**Congo-red:** Negative

**Immunohistochemistry:** Mesangial and peripheral capillary loop staining with anti-type III collagen

**3) HALLMARK/DEFINITIVE TEST:**

**Electron Microscopy:**

* **Low power:** Massive and global accumulation of fibrillar material of collagen type-III within the mesangial matrix and along the subendothelial aspect of a GBM. The lamina densa of GBM is not involved
* **High power**: Transverse band structure of fibrils, with a distinct periodicity of 60 nm. The fibrils form irregularly arranged bundles on longitudinal section and flower-like appearance on cross section.

**DISCUSSION:**

* Collagenofibrotic glomerulopathy (CFG) is a glomerular disease characterized by massive accumulation of congo red negative, non-immunologic derived deposits of atypical type III collagen fibrils within the mesangial matrix and sub-endothelial space
* There are 44 reported cases of CFG in the English language literature (33 adult cases and 13 pediatric cases)
* 9 of 13 pediatric cases shown to have a family history suggestive of autosomal recessive inheritance pattern
* Common clinical presentation: Proteinuria and edema with or without in adults and additionally hematuria is seen more frequently in pediatric cases. The characteristic physical abnormalities seen in Nail-patella syndrome are not seen in cases of CFG
* Majority of the patients reported to have high serum levels of procollagen peptide type III and suggests that being a useful and non-invasive marker of disease activity
* Disease course is more progressive and severe in pediatric-onset cases
* Native locations of collagen type-III are fetal skin, blood vessels, interstitium of the kidney however, should not be in the structures of glomeruli
* Cause and pathogenesis: Controversial in regards to nature of the disease being sporadic versus inherited and primary versus secondary
* Treatment: No specific treatment available. Main treatment consists of control of hypertension, edema, dialysis and transplant in ESKD. Role of systemic glucocorticoids still needs further clinical trials.

**REFERENCES:**

1. Arakawa M, Fueki H, Hirano H, et al: Idiopathic mesangio-degenerative glomerulopathy [Japanese]. Jpn JNephrol 21:914-915, 1979
2. Dombros N, Katz A: Nail patella-like renal lesions in the absence of skeletal abnormalities. Am J Kidney Dis 4:237-240, 1982
3. Ikeda K,Yokoyama H, Tomosugi N, Kida H, Ooshima A, Kobayashi K: Primary glomerular fibrosis: A new nephropathy caused by diffuse intra-glomerular increase in atypical type III collagen fibers. Clin Nephrol 33:155-159, 1990
4. Arakawa M, Yamanaka H: Collagenofibrotic glomerulopathy: A new type of primary glomerulopathy revealing massive collage deposition in the renal glomerulus, in Arakawa M,Yamanaka H (eds): Collagenofibrotic Glomerulopathy (ed 1). London, UK, Smith Gordon, 1991, pp 3-8
5. Yasuda T, Miki K, Nakamoto Y, et al: A case of nephrotic syndrome with massive deposition of collagen fibers in glomeruli: Collagen fiber deposit nephropathy [Japanese]. Jin to Toseki 17:115-120, 1984
6. Korbet SM, Schwartz MM, Lewis EJ. The fibrillary glomerulopathies. Am J Kidney Dis 1994;23;751
7. Yoshioka K, Takemura T, Tohda M, et al: Glomerular localization of type III collagen in human kidney disease. Kidney Int 35:1203-1211, 1989
8. Naruse K, Ito H, Moriki T, et al: Mesangial cell activation in the collagenofibrotic glomerulonephropathy. Case report and review of the literature. Virchows Arch 433:183-188, 1998
9. Nakazato Y, Okada H, Tajima S, et al: Interleukin-4 modulates collagen synthesis by human mesangial cells in a type-specific manner.Am J Physiol 270:F447-F453, 1996
10. Razzaque MS, Taguchi T: Expression of type III collagen mRNA in renal biopsy specimens of patients with idiopathic membranous glomerulonephritis. Clin Mol Pathol 49:M40-M42, 1996
11. Yasuda T, Imai H, Nakamoto Y, et al: Collagenofibrotic glomerulopathy:Asystemic disease.Am J Kidney Dis 33:123-127, 1999
12. Mizuiri S, Hasegawa A, Kikuchi A, Amagasaki Y, Nakamura N, Sakaguchi H: A case of collagenofibrotic glomerulopathy associated with hepatic perisinusoidal fibrosis. Nephron 63:183-187, 1993
13. Schwartz MM, Korbet SM, Lewis EJ: Immunotactoid glomerulopathy. JAm Soc Nephrol 13:1390-1397, 2002
14. Emanuel BS, Cannizzaro LA, Seyer JM, Myers JC: Human alpha 1(III) and alpha 2(V) procollagen genes are located on the long arm of chromosome 2. Proc Natl Acad Sci U SA82:3385-3389, 1985
15. Halila R, Peltonen L: Purification of human procollagen type III N-proteinase from placenta and preparation of antiserum. Biochem J 239:47-52, 1986
16. Soylemezoglu O, Wild G, Dalley AJ, et al: Urinary and serum type III collagen: Markers of renal fibrosis. Nephrol Dial Transplant 12:1883-1889, 1997
17. Keller F, Rehbein C, Schwarz A, et al: Increased procollagen III production in patients with kidney disease. Nephron 50:332-337, 1988
18. Oikarinen A, Autio P,Vuori J, et al: Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br J Dermatol 126:172- 178, 1992
19. Hisakawa N, Yasuoka N, Nishiya K, et al: Collagenofibrotic glomerulonephropathy associated with immune complex deposits.Am J Nephrol 18:134-141, 1998
20. Heptinstall’s Pathology of the Kidney, sixth edition

**Case # 3**

**PRESENTER:** Diana Murro, MD, PGY-2

**ATTENDING:** Paolo Gattuso, MD

**DIAGNOSIS:** Secondary poorly differentiated synovial sarcoma of the thyroid

**IMPORTANT DIFFERENTIAL DIAGNOSIS OF:**

* Medullary thyroid carcinoma
* Spindle epithelial tumor with thymus-like differentiation (SETTLE)
* Undifferentiated/anaplastic thyroid carcinoma
* Spindle-cell melanoma

**KEY CYTOLOGIC FEATURES:**

* Spindle cells with oval nuclei, delicate cytoplasm, granular chromatin and indistinct nucleoli.
* Epithelioid cells with round nuclei and ample pink cytoplasm.
* Conspicuous mitotic figures.
* Occasional cells with round to oval nuclei and prominent nucleoli.
* Some nuclei with longitudinal folds.
* Nuclear pleomorphism.
* Extracellular hyaline globules.

**DISCUSSION:**

Secondary thyroid malignancies:

* Patients are usually older than patients with primary thyroid malignancies (age >50 years) without female predominance.
* Presentation is either clinically occult or similar to primary thyroid tumor presentation (dysphagia, dysphonia).
* Most common primaries are breast, lung, and renal carcinoma, head and neck squamous cell carcinoma, melanoma and lymphoma.
* Time to metastases can be years (latency period 8 months-17 years).
* Metastatic sarcoma to the thyroid is very rare and has been described only in case reports.
* Although sarcomas may be confused with medullary thyroid carcinoma, pure spindle cell pattern medullary carcinoma is very rare.

Synovial sarcoma (SS) of the thyroid:

* Fewer than 10 cases have been reported likely due to the fact that only about 5% of synovial sarcomas occur anywhere in the head and neck region.
* Three cases of primary thyroid sarcoma sampled by FNA have been described and all were diagnosed as primary thyroid neoplasms (anaplastic thyroid carcinoma, follicular neoplasm and medullary thyroid carcinoma).
* One metastatic SS was reported from a patient with elbow SS and prior lung metastases. However, confirmatory FISH studies were not performed on the thyroid sample.

Fine needle aspiration (FNA) diagnosis of secondary thyroid malignancies

* Secondary malignancies represent 0.1% of thyroid FNAs.
* Occult primaries have been reported in 20-76% of cases, leading to a possible misdiagnosis of a primary thyroid neoplasm.
* FNA sensitivity for diagnosing a primary malignant lesion ranges from 64-100%.
* Focal tumor necrosis is found in 1/3 of secondary thyroid malignancies.
* Special studies for TTF-1 and thyroglobulin can rule out a thyroid primary. Pax-8 can be used to rule out undifferentiated/anaplastic thyroid carcinoma.
* FNA is most helpful when clinical history is known and can guide surgical decisions.
	+ Lobectomy for single metastasis
	+ Total thyroidectomy for multiple metastases
	+ No surgical treatment if patient has aggressive primary with poor survival

**REFERENCES:**

1. Boudin L, Fakhry N, Chetaille B, et al. Primary synovial sarcoma of the thyroid gland: case report and review of the literature. Case Rep Oncol. 2014;7(1):6-13.

2. Cheuk W, Jacobson AA, Chan JK. Spindle epithelial tumor with thymus-like differentiation (SETTLE): a distinctive malignant thyroid neoplasm with significant metastatic potential. Mod Pathol. 2000;13:1150-1155.

3. Cichoń S, Anielski R, Konturek A, Barczyński M, Cichoń W. Metastases to the thyroid gland: seventeen cases operated on in a single clinical center. Langenbecks Arch Surg. 2006;391(6):581-587.

4. Czech JM, Lichtor TR, Carney JA, van Heerden JA. Neoplasms metastatic to the thyroid gland. Surg Gynecol Obstet. 1982;155(4):503-505.

5. D’Arcy P, Maruwge W, Ryan BA, Brodin B. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability. Mol Cancer Res. 2008;6(1):127-138.

6. Gattuso P, Castelli MJ, Reyes C V. Fine needle aspiration cytology of metastatic sarcoma involving the thyroid. South Med J. 1989;82(9):1158-1160.

7. Haugen BR, Nawaz S, Cohn a, et al. Secondary malignancy of the thyroid gland: a case report and review of the literature. Thyroid. 1994;4(3):297-300.

8. Khadilkar UN, Lobo FD, Shahabuddin MD, Shetty A, Kini A. Sarcoma seeding to multinodular goitre--a diagnostic dilemma. Cytopathology. 1999;10(5):360-361.

9. Kikuchi I, Anbo J, Nakamura S, et al. Synovial sarcoma of the thyroid. Report of a case with aspiration cytology findings and gene analysis. Acta Cytol. 47(3):495-500.

10. Kim TY, Kim WB, Gong G, Hong SJ, Shong YK. Metastasis to the thyroid diagnosed by fine-needle aspiration biopsy. Clin Endocrinol (Oxf). 2005;62(2):236-241.

11. Luna-Ortiz K, Cano-Valdez AM, da Cunha IW, Mosqueda-Taylor A. Synovial sarcoma of the larynx treated by supraglottic laryngectomy: case report and literature review. Ear Nose Throat J. 2013;92(7):E20-E26.

12. Pusztaszeri M, Wang H, Cibas ES, et al. Fine-needle aspiration biopsy of secondary neoplasms of the thyroid gland: A multi-institutional study of 62 cases. Cancer Cytopathol. 2015;123(1):19-29.

13. Rosen IB, Walfish PG, Bain J, Bedard YC. Secondary malignancy of the thyroid gland and its management. Ann Surg Oncol. 1995;2(3):252-256.

14. Schmid KW, Hittmair A, Ofner C, Tötsch M, Ladurner D. Metastatic tumors in fine needle aspiration biopsy of the thyroid. Acta Cytol. 35(6):722-724.

15. Sturgis EM, Potter BO. Sarcomas of the head and neck region. Curr Opin Oncol. 2003;15:239-252.

16. Tong G-X, Hamele-Bena D, Wei X-J, O’Toole K. Fine-needle aspiration biopsy of monophasic variant of spindle epithelial tumor with thymus-like differentiation of the thyroid: report of one case and review of the literature. Diagn Cytopathol. 2007;35(2):113-119.

17. Yang L, Li W, Zhang H-Y. One case of synovial sarcoma extending from hypopharynx to thoracic segment of esophagus. Chin Med J (Engl). 2013;126(6):1200.

**Case # 4**

**PRESENTER:** Jamie Macagba Slade, M.D.

**ATTENDING:** Ritu Ghai, M.D.

**DIAGNOSIS:** Benign neural neoplasm of nerve sheath origin with a ganglion cell component and foci of heterologous epithelial differentiation (possible composite ganglioneuroma-paraganglioma with glandular component)

**IMPORTANT DIFFERENTIAL DIAGNOSIS:**

* Teratoma with neural overgrowth
* Ganglioneuroma with glandular differentiation
* Benign epithelioid schwannoma
* Benign glandular schwannoma
* Composite ganglioneuroma-paraganglioma with glandular component

**KEY MORPHOLOGICAL FEATURES:**

* Tumor composed of heterogenous morphology including:
	+ A major component consisting of a bland spindle cell proliferation (neural differentiation) with foci of ganglion-like cells
	+ A minor component consisting of large, epithelioid cells with abundant eosinophilic and granular cytoplasm
	+ Rare microscopic foci of glandular structures lined by cuboidal to columnar ciliated epithelium (epithelial differentiation)
* Electron microscopy findings of the spindle cell component consistent with peripheral nerve sheath differentiation. The epithelioid cell component contained mitochondria and lacked dense-core neurosecretory granules.

**DISCUSSION:**

* Neurogenic tumors are most commonly located in the posterior mediastinum and include schwannomas, neurofibromas, malignant peripheral nerve sheath tumors, ganglioneuroma, ganglioneuroblastoma, neuroblastoma, and paragangliomas.
* Neurogenic tumors, although rare, can be located in the anterior mediastinum.
* We presented an unusual tumor in the anterior mediastinum with predominant neurogenic differentiation with a ganglioniccomponent and focal heterologous glandular differentiation.

**REFERENCES:**

1. Shimosato Y, Mukai K, Matsuno Y. (2010). AFIP Atlas of Tumor Pathology, Tumors of the Mediastinum. *American Registry of Pathology*, Washington DC
2. Gattuso P, Plaza J, Moran C, Suster S, et al. (2010) Differential Diagnosis in Surgical Pathology. Saunders (Philadelphia) Ch 5. Thymus and Mediastinum.
3. Kim YC, Park HF, Cinn YW, Vandersteen (2001) Benign glandular schwannoma. *British Journal of Dermatology*; 145: 843-837
4. Rezanko T et al. (2012). Epithelioid schwannoma of soft tissue: unusual morphological variant causing a diagnostic dilemma. *Annals of Diagnostic Pathology*; 16 p 521-526.
5. Duwe B, Sterman D, Musani A (2005). Tumors of the Mediastinum. *Chest*. 128/4/October
6. Husain, A. High Yield Thoracic Pathology. Elsevier Saunders, Philadelphia, PA 2012.
7. Pytel P, Krausz T, Wollmann R, Utset M. Ganglioneuromatous paraganglioma of the cauda equina – a pathological case study. *Human Pathology* (2005) 36, 444-446.
8. Umemoto Y et al. Composite pheochromoctoma with ganglioneuroma in the adrenal gland: a case report. *Hinyokika Kiyo* 1998 Aug;44(8):575-7
9. Tohme CA, Mattar WE, Ghorra CS. Extra-adrenal composite pheochromocytoma-ganglioneuroma. *Saudi Med J.* 2006 Oct;27(10):1594-7.
10. Weiss S, Goldblum J. Enzinger and Weiss’s Soft Tissue Tumors 5th edition. Mosby Elsevier, Philadelphia, PA. Ch. 29 & 32.

**Case #5**

**PRESENTER:**  Alaa Alsadi, MD.

**ATTENDING:**  Ira Miller, MD, Ph.D.

**CASE HISTORY:** This patient is a 30 year-old male with a past medical history of diabetes type 1, hypertension, chronic kidney disease, and renal-pancreatic transplantation 10 years ago. He presented with a 20 lb weight loss over 10 months along with mild fever and night sweats. Physical exam showed diffuse lymphadenopathy. Initial blood workup was significant for a Hb of 5 g/dL. An enlarged inguinal lymph node was excised.

**KEY DIAGNOSTIC FEATURES OF OUR CASE**

* Intact reactive, secondary lymphoid follicle
* Expanded interfollicular zones with mature appearing, quiescent plasma cells and hyalinized vessels
* Plasma cells show lambda light chain isotype predominance by in situ hybridization
* No plasmablasts are identified in the mantle zone
* HHV8 immunostain is negative
* Flow cytometry showed monotypic lambda+ plasma cells without an associated monotypic B cell population
* Plasma immunoglobulins show IgG of 2478 mg/dl, which is 85% IgG lambda on immunoelectrophoresis, with no decrease in levels of IgA or IgM. Electrophoresis histogram is consistent with the presence of an IgG lambda paraprotein, possibly with diffuse background IgG lambda increase. Molecular studies for clonality were technically unsuccessful

**DIAGNOSIS:** Post-transplant lymphoproliferative disease with features of multicentric Castleman disease, plasma cell variant (HHV8-negative), with associated autoimmune hemolytic anemia.

**DIFFERENTIAL DIAGNOSIS:**

* PTLD, monomorphic, plasmacytoma-like:

Can be nodal or extranodal. Can be EBV+. More destructive appearing than our case.

* PTLD, early changes, plasmacytic hyperplasia:

Localized to tonsils or lymph node.

* Reactive lymphadenopathy with plasma cell hyperplasia:

Occurs outside of transplant setting. Nodal architecture (sinuses, etc.) is more preserved than in our case.

* Lymphoplasmacytic lymphoma:

Presents as a systemic neoplasm with marrow involvement in nearly all cases

Lymph nodes may be involved

Paraprotein is nearly always IgM (Waldenstrom macroglobulinemia)

Plasma cells are admixed with variable proportions of mature lymphocytes and plasmacytoid lymphocytes

* Marginal zone lymphoma with extensive plasmacytic differentiation:

Variant of marginal zone B cell lymphoma where clonal B cells cannot be identified (plasmacytoma)

Presents similar to MALT lymphoma, with localized disease

Can be histologically identical to our case.

* Multicentric Castleman Disease, Plasma cell variant:
1. Half of cases are associated with HIV and show mantle zone IgM lambda restricted plasmablasts infected with HHV8.
	* + - Viral IL6 and human IL6 are pathogenic
			- May evolve to “micro lymphomas” and overt plasmablastic lymphoma
			- Poor prognosis
2. Other cases occur in settings of immunocompromise or immune dysregulation.
	* + - Usually polytypic. It is uncertain if monotypia has been reported in this entity.
			- Few cases have been well described in the literature
			- Human IL6 considered to be important in pathogenesis

**MANAGEMENT AND FOLLOW UP:**

The patient’s dose of cyclosporin was reduced. His anemia completely resolved. Follow up serum studies showed no detectible paraproteins and normalization of all quantitative immunoglobulin studies.

**DISCUSSION:**

The discussed case shows partial clinical and morphological characteristics of two different pathological groups:

* First group is the post-transplant lymphoproliferative diseases (PTLD);  of this group, our case is most morphologically similar to plasmacytic hyperplasia, however, this entity is not typically a systemic process, is polytypic, and usually occurs early post-transplant.
* Second group is the low grade lymphoproliferative diseases; of this group, our case is most morphologically similar to marginal zone B cell lymphoma with extensive plasmacytic differentiation, however, this entity is not typically a systemic process and is not (by the WHO definition ) a recognized subtype of PTLD.

The rapid clinical response to reducing immune suppression in our case (in a non-clonal PTLD-fashion) as well as the striking morphological similarity to Castleman’ disease (a systemic non clonal entity) lead to our hybrid diagnosis of a post-transplant lymphoproliferative disease with features of Castleman disease. A few cases of post-transplant lymphoproliferative disease are reported in the literature.

**REFERENCES:**

1. Marginal zone B cell lymphomas with extensive plasmacytic differentiation are neoplasms of precursor plasma cells. Meyerson HJ1, Bailey J, Miedler J, Olobatuyi F. Cytometry B Clin Cytom. 2011 Mar;80(2):71-82. doi: 10.1002/cyto.b.20571. Epub 2010 Nov 20.
2. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, Gazzard B, Bower M. Ann Oncol. 2009;20(4):775.
3. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Du MQ, Liu H, Diss TC, et al. Blood 2001;97:2130–2136. [PubMed: 11264181]
4. Successful treatment of iatrogenic multicentric Castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient. Speicher DJ1, Sehu MM, Mollee P, Shen L, Johnson NW, Faoagali JL. Am J Transplant. 2014 May;14(5):1207-13. doi: 10.1111/ajt.12693. Epub 2014 Mar 26.
5. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Fajgenbaum DC1, van Rhee F, Nabel CS. Blood. 2014 May 8;123(19):2924-33. doi: 10.1182/blood-2013-12-545087. Epub 2014 Mar 12.

**Case #6**

**PRESENTER:** Aparna Harbhajanka, MD

**ATTENDING:** Paolo Gattuso, MD

**CASE HISTORY:** A 55-year-old female presented with history of recurrent tumor. A computed tomography (CT) scan of the primary tumor showed well-defined punched out defect with sharply demarcated margins involving the mandible in the region of teeth numbers 19 and 20 with nonenhancing soft tissue. She had a segmental resection of the left mandible with neck dissection. After 4 years she presented with an enlarging mass of the left side of the jaw over months and shifting of the left jaw inferiorly and open mouth deformity. Radiological examination showed approximately 2.9 x 3.0 cm enhancing lesion in the left buccal space most likely representing recurrent tumor.

**DIAGNOSIS:** Clear cell odontogenic carcinoma

**IMPORTANT DIFFERENTIAL DIAGNOSES:**

* Clear cell salivary gland carcinoma
* Clear cell Ameloblastoma
* Metastatic Clear cell renal cell carcinoma

**DISCUSSION:**

* Rare neoplasm with histological features and immunophenotype of clear cell salivary gland carcinoma
* Hansen et al (1985) described the first case
* Odontogenic tumor of the jaw
* Mandible > maxilla
* Posterior > anterior site
* Fifth to seventh decades
* Etiology of tumor is unknown
	+ Origin from odontogenic epithelium
* Histology:
	+ Solid sheets and nests of clear cells
	+ Three patterns
		- Biphasic -clear cell component intermixed with eosinophilic cell component
		- Monophasic pattern - clear cells
		- Ameloblastomatous - clear cell nests with peripheral nuclear palisading (least common).
* IHC: CK8/18 and CK19 positive, EMA and S100 ocassionally positive.
* Molecular: EWSR1-ATF1 translocation
* Treatment:
	+ Best disease free survival is radical surgical resection
	+ Adjuvant therapy post surgery unclear
* Key points:
	+ Clear cell odontogenic carcinoma RARE
	+ Can share microscopic features with Clear cell salivary gland carcinoma
	+ Need to rule out metastatic RCC
	+ Molecular: EWSR1-ATF1 translocation
	+ No standardized treatment
		- Surgical resection yields best results
		- Chemo and radiation may be helpful for recurrent disease

**REFERENCES:**

1. Hansen LS, Eversole LR, Green TL, Powell NB. Clear cell odontogenic tumor--a new histologic variant with aggressive potential. Head & neck surgery 1985;8:115-23.

2. Kramer IR, Pindborg JJ, Shear M. The WHO Histological Typing of Odontogenic Tumours. A commentary on the Second Edition. Cancer 1992;70:2988-94.

3. Barnes L, Eveson JW, Reichart PA, Sidransky D. WHO Classification of Tumors, Pathology and Genetics of Head and Neck Tumours. Lyon, France: IARC Press; 2005. WHO histological classification of odontogenic tumours; p. 284.

4. Bang G, Koppang HS, Hansen LS, et al. Clear cell odontogenic carcinoma: report of three cases with pulmonary and lymph node metastases. J Oral Pathol Med 1989;18:113-8.

5. Brinck U, Gunawan B, Schulten HJ, Pinzon W, Fischer U, Fuzesi L. Clear-cell odontogenic carcinoma with pulmonary metastases resembling pulmonary meningothelial-like nodules. Virchows Arch 2001;438:412-7.